Role and Mechanisms of cGMP-PDE Compartmentation in Cardiac Stress
Role and Mechanisms of cGMP-PDE Compartmentation in Cardiac Stress
批准号:
9189461
负责人:
Kristen Kokkonen-Simon
金额:
$4.36万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-08-16 至 2019-08-15
关键词:
AddressAffectAngiotensin ReceptorAnimalsAttenuatedCardiacCardiac MyocytesCardiovascular DiseasesCatabolismCategoriesCause of DeathCellsClinical TrialsCyclic GMPCyclic GMP-Dependent Protein KinasesDataDependenceDiagnosisDiseaseDrug TargetingEFRACEconomicsElectron MicroscopyEnalaprilEnzymesErectile dysfunctionEstrogensFemaleGene DeletionGeneticGonadal Steroid HormonesGuanylate CyclaseHealth Care CostsHeartHeart DiseasesHeart HypertrophyHeart failureHormonesHumanIschemiaKnockout MiceLinkMental DepressionModelingMolecularMorbidity - disease rateMusMyocardialNatriuretic PeptidesNeprilysinNitric OxidePathway interactionsPatientsPeptide ReceptorPharmaceutical PreparationsPhosphodiesterase InhibitorsPlayPostmenopauseProtein IsoformsProteomePulmonary HypertensionRegulationRodentRoleSignal PathwaySignal TransductionSoluble Guanylate CyclaseSpecificityStressTestingTherapeuticTreatment EfficacyUnited StatesWomanabstractingbaseeffective therapyfallsgene synthesisheart functionimprovedin vivoinhibitor/antagonistinterestmalenext generation sequencingnovelphosphoric diester hydrolasepressurereceptor couplingsexstressortooltranscriptome
中文摘要
摘要
英文摘要
Abstract
Heart failure (HF) is a leading cause of death globally, affecting almost 6 million people in the United
States alone. Up to 50% of these patients will die within five years of diagnosis, making elucidation of
the mechanistic underpinnings imperative so they can be evaluated for therapeutic potential.
Evidence from our lab has shown that phosphodiesterases (PDEs) that degrade cyclic guanosine
monophosphate (cGMP) have great utility as druggable targets in heart failure. These PDEs
ultimately block protein kinase G (PKG) signaling, a known cardioprotective pathway; hence blockade
of PDE activity results in cardioprotection. Several cGMP-specific PDEs are present in the heart,
namely the nitric oxide-linked PDE5a and the natriuretic peptide-linked PDE9a. These PDEs are
compartmentalized to specific regions of the cell, although little is known about this compartmentation
for PDE5, and nothing is known for PDE9. Part of this proposal aims to study this compartmentation
using novel molecular tools such as compartment-targeted PKG inhibitors and tagged PDEs that can
be used to determine subcellular localization and compartment-specific proteomes. Knowing the
specifics of the PDE5 and PDE9 compartments may clarify how these PDEs can be manipulated for
therapeutics. Previous in vivo studies have demonstrated that inhibition of PDE5 has great
therapeutic utility in male animal HF models, but has fallen short in female mice lacking estrogen
(comparable to HF in postmenopausal women) and in human HF with preserved ejection fraction
patients. These shortcomings are due to the regulation of nitric oxide by estrogen and the depression
of nitric oxide levels in HF, respectively. Recently we revealed that inhibition or genetic deletion of
PDE9a, the other cGMP-specific PDE in the heart, attenuates cardiac hypertrophy in male mice. The
PDE9 pathway acts independently of the nitric oxide/PDE5 pathway, making it a promising drug
target in situations where PDE5 inhibition is ineffective. We hypothesize that inhibition of PDE9 will
result in improved cardiac function in rodent pressure-overload models independent of sex and sex
hormone status. This hypothesis will be tested in a female pressure-overload HF model using C57Bl6
mice treated with PDE9 inhibitors and PDE9a knockout mice lacking estrogen.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金